Related Experiment Video
Updated: Sep 9, 2025
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Targeting ARPC1B + Cancer Stem Cells to Sensitise Pancreatic Cancer to Gemcitabine Treatment
Yang Wu1, Jianpeng Zhang2, Weixiong Zhu3
1Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Abstract:
ARPC1B+ cancer stem cells (CSCs) in pancreatic cancer are identified as a subpopulation resistant to gemcitabine. In our study, drug repositioning, molecular docking, and surface plasmon resonance (SPR) technique jointly revealed that CK-636 can directly target ARPC1B protein with high affinity. In vitro cytotoxicity, ex vivo organoid cultures, in vivo xenograft and orthotopic gemcitabine-resistant pancreatic cancer model demonstrated that combination therapy of gemcitabine plus CK-636 showed a superior anti-tumor effect compared with gemcitabine monotherapy. Our study demonstrated that CK-636 can act as a rational adjuvant to overcome gemcitabine resistance in pancreatic cancer therapy.
Insights
Gemcitabine-resistant pancreatic cancer stem cells (CSCs) can be targeted by CK-636. Combination therapy with gemcitabine plus CK-636 demonstrates superior anti-tumor effects, overcoming drug resistance.
Area of Science:
- Oncology
- Cancer Biology
- Drug Discovery
Background:
- Pancreatic cancer harbors gemcitabine-resistant cancer stem cells (CSCs) expressing ARPC1B.
- Developing strategies to overcome gemcitabine resistance is crucial for improving patient outcomes.
Discussion:
- CK-636 was identified as a potential therapeutic agent targeting ARPC1B.
- Drug repositioning, molecular docking, and SPR confirmed CK-636's high affinity for ARPC1B.
- Combination therapy of gemcitabine and CK-636 demonstrated significant anti-tumor activity.
Key Insights:
- CK-636 effectively targets ARPC1B, a key protein in gemcitabine-resistant pancreatic CSCs.
- In vitro and in vivo models confirmed the synergistic anti-tumor effect of gemcitabine plus CK-636.
- This combination therapy overcomes gemcitabine resistance in pancreatic cancer.
Outlook:
- CK-636 shows promise as an adjuvant therapy to enhance gemcitabine efficacy.
- Further clinical investigation is warranted to validate CK-636's role in pancreatic cancer treatment.
- This approach could offer a new therapeutic strategy for refractory pancreatic cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:40Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...